SCHEMBL1963685

SCHEMBL1963685

COc1cc(C=Cc2nc3ccccc3c(=O)n2-c2ccccc2)ccc1O

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 10/20 0.88
KMT2A Q03164 10/20 0.88
MAPT P10636 5/20 0.86
GLA P06280 1/20 0.86
PKM P14618 1/20 0.86
MCL1 Q07820 1/20 0.86
TDP1 Q9NUW8 1/20 0.86
GAA P10253 3/20 0.81
POLB P06746 4/20 0.76
TP53 P04637 4/20 0.74
LMNA P02545 2/20 0.74
PSMD14 O00487 1/20 0.74
KDM4E B2RXH2 1/20 0.73
ALDH1A1 P00352 1/20 0.73
PSEN1 P49768 1/20 0.67
PSEN2 P49810 1/20 0.67
KCNH2 Q12809 1/20 0.67
APH1B Q8WW43 1/20 0.67
NCSTN Q92542 1/20 0.67
APH1A Q96BI3 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1963682 1.00 MEN1 (0.88) MEN1KMT2AMAPTGLAPKM
SCHEMBL4973403 0.91 MAPT (0.88) MEN1KMT2AMAPTGLAPKM
SCHEMBL4973398 0.91 MAPT (0.88) MEN1KMT2AMAPTGLAPKM
Hydrochloric Acid SCHEMBL1963370 0.90 MAPT (0.86) MEN1KMT2AMAPTGLAPKM
Hydrochloric Acid SCHEMBL1963371 0.90 MAPT (0.86) MEN1KMT2AMAPTGLAPKM
SCHEMBL6098584 0.87 MAPT (0.71) MEN1KMT2AMAPTGLAPKM
SCHEMBL6098875 0.87 MAPT (0.71) MEN1KMT2AMAPTGLAPKM
SCHEMBL1961879 0.83 MEN1 (0.87) MEN1KMT2AMAPTTDP1GAA
SCHEMBL1961880 0.83 MEN1 (0.87) MEN1KMT2AMAPTTDP1GAA
SCHEMBL1961884 0.82 MAPT (0.84) MEN1KMT2AMAPTGLAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140155417-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES, INC. (US) 2014-06-05 US disclosed
US-8552009-B2 Substituted pyrimido 4.5-d pyrimidin-4-one compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. 2013-10-08 US disclosed
CN-101355946-B Compounds for modulating TRPV3 function HYDRA BIOSCIENCES INC 2013-05-08 CN disclosed
US-20110144135-A1 Compounds for Modulating TRPV3 Function HYDRA BIOSCIENCES, INC. (US) 2011-06-16 US disclosed
US-7893260-B2 Substituted quinazolin-4-one compounds for antagonizing TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2011-02-22 US disclosed
US-20100152209-A1 Compounds for Modulating TRPV3 Function HYDRA BIOSCIENCES INC. (US) 2010-06-17 US disclosed
EP-1954283-A2 COMPOUNDS FOR MODULATING TRPV3 FUNCTION Hydra Biosciences, Inc. (US) 2008-08-13 EP disclosed
US-20070179164-A1 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2007-08-02 US disclosed
WO-2007056124-A2 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155417-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION TRPV3, TRPV1, TRPV4 MEN1 4683/4885KMT2A 4347/4885MAPT 1751/4885
US-20100152209-A1 Compounds for Modulating TRPV3 Function TRPV3, TRPV1, TRPV4 MEN1 4683/4885KMT2A 4347/4885MAPT 1751/4885
US-20070179164-A1 Compounds for modulating TRPV3 function TRPV3, TRPV1, TRPV4 MEN1 4683/4885KMT2A 4347/4885MAPT 1751/4885
US-20110144135-A1 Compounds for Modulating TRPV3 Function TRPV3, TRPV1, TRPV4 MEN1 4683/4885KMT2A 4347/4885MAPT 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.